In this context, we aimed to identify the expression patterns of circadian clock proteins by immunohistochemistry, particularly PER1/2/3, CRY1/2, BMAL1 and NR1D2 in a cohort of patients with CRC and examine their role in the progression of the disease and outcome of patients. This evidence concerns the gene NR1D2 and colorectal carcinoma.